Fidelity Investments
HRTX icon

Fidelity Investments’s Heron Therapeutics HRTX Stock Holding History

Fidelity Investments’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.6K Sell
58,195
-26,002
-31% -$30.1K ﹤0.01% 4158
2025
Q4 		$109K Buy
84,197
+36,803
+78% +$45.4K ﹤0.01% 3714
2025
Q3 		$59.7K Sell
47,394
-3,926
-8% -$6.22K ﹤0.01% 3893
2025
Q2 		$106K Buy
51,320
+549
+1% +$1.12K ﹤0.01% 3582
2025
Q1 		$112K Sell
50,771
-141,115
-74% -$274K ﹤0.01% 3508
2024
Q4 		$294K Sell
191,886
-240,020
-56% -$389K ﹤0.01% 3113
2024
Q3 		$859K Buy
431,906
+89,601
+26% +$214K ﹤0.01% 2643
2024
Q2 		$1.2M Buy
342,305
+22,362
+7% +$68.7K ﹤0.01% 2473
2024
Q1 		$886K Buy
319,943
+300
+0.1% +$754 ﹤0.01% 2541
2023
Q4 		$543K Buy
319,643
+39,144
+14% +$43.1K ﹤0.01% 2664
2023
Q3 		$289K Buy
280,499
+4,272
+2% +$6.08K ﹤0.01% 2767
2023
Q2 		$320K Buy
276,227
+139,459
+102% +$249K ﹤0.01% 2801
2023
Q1 		$207K Buy
136,768
+648
+0.5% +$1.62K ﹤0.01% 2962
2022
Q4 		$340K Sell
136,120
-6,135
-4% -$19.8K ﹤0.01% 2844
2022
Q3 		$601K Buy
142,255
+2,087
+1% +$8.17K ﹤0.01% 2739
2022
Q2 		$391K Buy
140,168
+5,369
+4% +$21.6K ﹤0.01% 2920
2022
Q1 		$771K Buy
134,799
+7,821
+6% +$57.2K ﹤0.01% 2853
2021
Q4 		$1.16M Sell
126,978
-513,632
-80% -$5.24M ﹤0.01% 2658
2021
Q3 		$6.85M Buy
640,610
+9,627
+2% +$117K ﹤0.01% 2265
2021
Q2 		$9.79M Sell
630,983
-395,868
-39% -$6.3M ﹤0.01% 2118
2021
Q1 		$16.6M Sell
1,026,851
-63,965
-6% -$1.14M ﹤0.01% 1857
2020
Q4 		$23.1M Sell
1,090,816
-35,072
-3% -$610K ﹤0.01% 1654
2020
Q3 		$16.7M Sell
1,125,888
-791,880
-41% -$12.4M ﹤0.01% 1636
2020
Q2 		$28.2M Sell
1,917,768
-601,834
-24% -$9.89M ﹤0.01% 1412
2020
Q1 		$29.6M Sell
2,519,602
-4,062,808
-62% -$76.4M ﹤0.01% 1246
2019
Q4 		$155M Sell
6,582,410
-1,914,379
-23% -$42.4M 0.02% 747
2019
Q3 		$157M Buy
8,496,789
+414,611
+5% +$7.63M 0.02% 706
2019
Q2 		$150M Sell
8,082,178
-391,669
-5% -$7.82M 0.02% 752
2019
Q1 		$207M Buy
8,473,847
+439,044
+5% +$11.5M 0.02% 631
2018
Q4 		$208M Sell
8,034,803
-1,554,710
-16% -$42.7M 0.03% 579
2018
Q3 		$304M Sell
9,589,513
-1,701,443
-15% -$63.4M 0.03% 505
2018
Q2 		$439M Buy
11,290,956
+693,699
+7% +$22.1M 0.05% 360
2018
Q1 		$292M Buy
10,597,257
+975,248
+10% +$22.1M 0.03% 526
2017
Q4 		$174M Buy
9,622,009
+1,506,500
+19% +$24.6M 0.02% 739
2017
Q3 		$131M Buy
8,115,509
+66,274
+0.8% +$1.04M 0.02% 856
2017
Q2 		$111M Buy
8,049,235
+18,355
+0.2% +$266K 0.01% 931
2017
Q1 		$120M Buy
8,030,880
+2,158,041
+37% +$29.9M 0.02% 909
2016
Q4 		$76.9M Buy
5,872,839
+20,545
+0.4% +$322K 0.01% 1119
2016
Q3 		$101M Buy
5,852,294
+358,874
+7% +$6.66M 0.01% 969
2016
Q2 		$99.2M Buy
5,493,420
+63,968
+1% +$1.25M 0.01% 978
2016
Q1 		$103M Buy
5,429,452
+39,154
+0.7% +$773K 0.01% 951
2015
Q4 		$144M Buy
5,390,298
+40,996
+0.8% +$1.1M 0.02% 807
2015
Q3 		$131M Buy
5,349,302
+3,582,141
+203% +$119M 0.02% 837
2015
Q2 		$55.1M Buy
+1,767,161
New +$33.2M 0.01% 1299
2014
Q3 		– Sell
-456,320
Closed -$5.62M – 2798
2014
Q2 		$5.62M Sell
456,320
-31,500
-6% -$376K ﹤0.01% 2211
2014
Q1 		$6.79M Buy
+487,820
New +$6.52M ﹤0.01% 2132

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Fidelity Investments's HRTX Position: Q1 2026 in Review

Fidelity Investments reduced its Heron Therapeutics (HRTX) stake by 31% in Q1 2026, selling an estimated $30.1K and leaving 58,195 shares worth $46.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4158.

Fidelity Investments first reported a position in HRTX in Q1 2014 and has held it in 46 quarters since. The position peaked at $439M in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Fidelity Investments held 58,195 shares of Heron Therapeutics worth $46.6K as of Q1 2026.
  • Fidelity Investments sold 26,002 Heron Therapeutics shares in Q1 2026, an estimated $30.1K.
  • Heron Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #4158 holding.
  • Fidelity Investments first reported a position in Heron Therapeutics in Q1 2014 and has held it in 46 quarters since.
  • Fidelity Investments's Heron Therapeutics position peaked at $439M in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.